Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Methotrexate Stories

2012-06-06 12:30:57

Safety results were similar between groups Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tocilizumab monotherapy is more effective than adalimumab monotherapy in the treatment of rheumatoid arthritis (RA) based on change from baseline in DAS28 (-3.3 vs. -1.8, p<0.0001) at week 24. The ADACTA trial, conducted in 325 patients with RA showed that tocilizumab was more effective than adalimumab for DAS28 remission (39.9%...

2012-06-04 02:26:15

WEST CONSHOHOCKEN, Pa., June 4, 2012 /PRNewswire/ -- BTG International Inc., the specialist healthcare company, today announces the presentation of data on Voraxaze(®) (glucarpidase) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1-5, 2012 in Chicago, Illinois. BTG received US regulatory approval for Voraxaze(®) on 17 January 2012, and the data presented formed a key part of the Biologics License Application (BLA) submission. Clinical data on the...

2012-06-01 02:23:47

BRUSSELS, June 1, 2012 /PRNewswire/ -- UCB, a leading biopharmaceutical company, is sponsoring several data presentations for its immunology portfolio at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Berlin, Germany, June 6-9, 2012. "We are pleased to show our continued commitment to improving the lives of those living with autoimmune diseases," said Professor Dr. Iris Loew-Friedrich, Chief Medical Officer and Executive Vice President, UCB. "The...

2012-05-01 11:40:28

High-dose steroids found to significantly increase infection risk Children with juvenile idiopathic arthritis (JIA) have higher rates of hospitalized bacterial infection than children without JIA according to an observational study appearing in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR). The findings show that the risk of infection among JIA patients was significantly increased with use of high-dose...

2012-04-30 02:25:48

WEST CONSHOHOCKEN, Pa., April 30, 2012 /PRNewswire/ -- BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze® (glucarpidase) in the US. Voraxaze® is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Voraxaze® breaks down methotrexate into inactive metabolites which are then eliminated from the body by routes...

2012-02-22 06:00:00

BRUSSELS, Feb. 22, 2012 /PRNewswire/ -- UCB today announced the start of C-EARLY(TM) - a phase III study that will evaluate the efficacy and safety of Cimzia® (certolizumab pegol) in combination with methotrexate (MTX) for inducing and sustaining clinical response in adults with early, progressive, active, moderate to severe rheumatoid arthritis (RA), who have not previously been treated with disease-modifying antirheumatic drugs (DMARDs). The study also aims to assess whether the...

FDA Rushes To Fix Shortage Of Cancer Drugs
2012-02-21 15:03:31

The Food and Drug Administration (FDA) announced plans on Tuesday to help resupply the U.S. with two leading cancer drugs. The agency said they will address shortages of two leading cancer drugs by allowing one of them to be imported from abroard, and rush approval for a new manufacturer to make the second. "We're not out of the woods," Dr Sandra L Kweder of the Food and Drug Administration's drug center told the New York Times. "But these two particular shortages have been very, very...

2012-02-21 11:05:00

LAKE FOREST, Ill., Feb. 21, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, announced today that it began shipping 31,000 vials of 1-gram methotrexate to U.S. hospitals and treatment centers on Monday, enough for one month's U.S. demand. In addition, Hospira continues to work closely with the U.S. Food and Drug Administration (FDA) to ensure that by mid-March the company will have produced enough supply of this...

2012-02-16 10:59:00

As the world´s largest professional society concerned with the causes and treatment of blood disorders, many of ASH's more than 16,000 members are on the front lines of dealing with the country´s severe shortage of methotrexate, a drug critical in the treatment of children with acute lymphocytic leukemia (ALL). This morning the Food and Drug Administration (FDA) reported that two manufacturers plan additional releases at the end of this week, at the end of February, and continuing...

2012-02-15 13:02:00

WASHINGTON, Feb. 15, 2012 /PRNewswire-USNewswire/ -- As the world's largest professional society concerned with the causes and treatment of blood disorders, many of our more than 16,000 members are on the front lines of dealing with the country's severe shortage of methotrexate, a drug critical in the treatment of children with acute lymphocytic leukemia (ALL). This morning the Food and Drug Administration (FDA) reported that two manufacturers plan additional releases at the end of this week,...